3,482 Shares in Novartis AG (NYSE:NVS) Bought by Michels Family Financial LLC

Michels Family Financial LLC bought a new position in shares of Novartis AG (NYSE:NVS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 3,482 shares of the company's stock, valued at approximately $339,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Human Investing LLC bought a new position in Novartis during the 4th quarter worth $25,000. Raiffeisen Bank International AG bought a new position in shares of Novartis during the fourth quarter worth about $25,000. Union Bancaire Privee UBP SA acquired a new position in shares of Novartis in the fourth quarter worth approximately $27,000. Bellwether Advisors LLC bought a new stake in Novartis in the fourth quarter valued at approximately $38,000. Finally, Fourth Dimension Wealth LLC acquired a new stake in Novartis during the 4th quarter valued at approximately $39,000. 13.12% of the stock is owned by institutional investors.

Novartis Stock Up 0.3%

NYSE:NVS traded up $0.34 on Thursday, hitting $112.21. The stock had a trading volume of 458,621 shares, compared to its average volume of 1,585,764. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. Novartis AG has a 52 week low of $96.06 and a 52 week high of $120.92. The business's fifty day moving average is $109.89 and its 200 day moving average is $105.97. The company has a market cap of $237.02 billion, a PE ratio of 19.07, a P/E/G ratio of 1.70 and a beta of 0.60.

Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, beating analysts' consensus estimates of $2.12 by $0.16. Novartis had a net margin of 23.56% and a return on equity of 37.24%. The business had revenue of $13.23 billion during the quarter, compared to analyst estimates of $12.92 billion. During the same quarter in the previous year, the business posted $1.80 EPS. Novartis's quarterly revenue was up 11.9% on a year-over-year basis. On average, equities research analysts expect that Novartis AG will post 8.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on NVS. Deutsche Bank Aktiengesellschaft raised shares of Novartis from a "hold" rating to a "buy" rating in a research note on Tuesday, February 4th. Morgan Stanley assumed coverage on shares of Novartis in a research report on Wednesday, February 12th. They set an "underweight" rating on the stock. BNP Paribas raised Novartis to a "strong-buy" rating in a research report on Tuesday, April 15th. Wall Street Zen upgraded Novartis from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 8th. Finally, UBS Group reissued a "neutral" rating on shares of Novartis in a research note on Thursday, February 13th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.